Pharmacotherapy options for the management of subjective tinnitus: a systematic review and network meta-analysis

source extracted confidence: high 2026-04-09
#humans #randomized-controlled-trials-as-topic #tinnitus

Pharmacotherapy options for the management of subjective tinnitus: a systematic review and network meta-analysis

Li et al., 2025 | BMJ Open | Systematic Review

Citation

Li Peifan, Che Chenhao, ... Sun Shan. Pharmacotherapy options for the management of subjective tinnitus: a systematic review and network meta-analysis. BMJ Open. 2025-May-28;15(5):e096995. doi:10.1136/bmjopen-2024-096995

Abstract

OBJECTIVES: This study aims to compare the outcomes of different pharmacotherapies for subjective tinnitus patients using a comprehensive network meta-analysis. DESIGN: Systematic review and network meta-analysis. DATA SOURCES: PubMed, EMBASE, Web of Science and CINAHL Complete databases were searched from inception until 6 March 2025. ELIGIBILITY CRITERIA: Randomised controlled trials (RCTs) comparing pharmacotherapy treatment effects for subjective tinnitus patients were included with tinnitus severity as the primary outcome, and annoyance and tinnitus loudness as secondary outcomes. DATA EXTRACTION AND SYNTHESIS: Two reviewers independently retrieved and screened full articles using a standardised and prepiloted Excel form. Network meta-analysis was conducted with heterogeneity, study risk of bias (ROB), risk of publication bias and certainty of evidence examined using I2, τ2, ROB2, funnel plots and Grading of Recommendations, Assessment, Development, and Evaluation assessments. RESULTS: Sixty full-text RCTs from 21 countries were included in the analysis with 22% low ROB, 58% some concerns and 20% high ROB. The heterogeneity parameter I2 was 0.67 (95% CI 0.33 to 0.84), 0 (95% CI 0 to 0.9) and 0.63 (95% CI 0 to 0.89) for the severity, annoyance and loudness network analysis, respectively. The only significant publication bias assessment by Egger's test was detected in the loudness network analysis (p<0.05). Ginkgo biloba with vitamin (standardised mean differences (SMD): -3.11, 95% CI (-4.15 to -2.06)), acamprosate (SMD: -0.88, 95% CI (-1.81 to -0.04)) and fluoxetine (SMD: -3.28, 95% CI (-4.23 to -2.34)) ranked first in severity, annoyance and loudness, respectively, compared with placebo. There are three significant inconsistent comparisons observed in the severity network and ranked with very low certainty of evidence by GRADE assessment. CONCLUSIONS: This meta-analysis found that antioxidant supplementation, such as Ginkgo biloba, and vitamins and gamma-aminobutyric acid agonists, represented by acamprosate, could be promising treatments for subjective tinnitus. Further trials with rigorous design and larger sample sizes are necessary to supplement the current evidence. TRIAL REGISTRATION NUMBER: INPLASY202480066.

Key Findings

Sixty full-text RCTs from 21 countries were included in the analysis with 22% low ROB, 58% some concerns and 20% high ROB. The heterogeneity parameter I2 was 0.67 (95% CI 0.33 to 0.84), 0 (95% CI 0 to 0.9) and 0.63 (95% CI 0 to 0.89) for the severity, annoyance and loudness network analysis, respectively. The only significant publication bias assessment by Egger's test was detected in the loudness network analysis (p<0.05). Ginkgo biloba with vitamin (standardised mean differences (SMD): -3.11,

Outcomes Measured

  • Requires manual extraction

Population

Field Value
Population See abstract
Sample Size See abstract
Age Range See abstract
Condition See abstract

MeSH Terms

  • Humans
  • Randomized Controlled Trials as Topic
  • Tinnitus

Evidence Classification

  • Level: Systematic Review
  • Publication Types: Journal Article, Network Meta-Analysis, Systematic Review
  • Vertical: ginkgo

Provenance

Source extracted via PubMed E-utilities API on 2026-04-09